<DOC>
	<DOCNO>NCT00610168</DOCNO>
	<brief_summary>The purpose study assess efficacy safety repeat dTpa booster adult 10 year previous booster vaccination dTpa prior clinical study . Only subject receive booster vaccination previous clinical study eligible participation study .</brief_summary>
	<brief_title>Immunogenicity &amp; Reactogenicity Boostrix 10 Years After Previous Booster Vaccination .</brief_title>
	<detailed_description>This Protocol Posting update order comply FDA AA , Sep 2007 .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Subjects receive dTpa vaccine Td pa vaccine study 263855/004 . A male female subject , recruit 10 year booster vaccination study 263855/004 . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential , , childbearing potential , must use adequate contraception 30 day prior vaccination continue 2 month completion vaccination series . Written inform consent obtain subject . Use investigational nonregistered product study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior booster vaccination plan administration active study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous booster vaccination tetanus , diphtheria pertussis since last dose receive study 263855/004 . History document diphtheria , tetanus , pertussis disease . Any confirm suspected immunosuppressive immunodeficiency condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine . Administration immunoglobulins and/or blood product within three month precede booster dose plan administration study period . Occurrence transient thrombocytopenia neurological complication follow early immunisation diphtheria and/or tetanus . Occurrence follow adverse event previous administration DTP vaccine : hypersensitivity reaction component vaccine , encephalopathy unknown aetiology occur within 7 day follow previous vaccination pertussiscontaining vaccine , fever &gt; = 40Â°C within 48 hour vaccination due another identifiable cause , collapse shocklike state ( hypotonichyporesponsiveness episode ) within 48 hour vaccination , convulsion without fever , occur within 3 day vaccination . Acute disease time enrolment . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution within 2 month completion vaccination series .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>dTpa vaccine</keyword>
	<keyword>pertussis</keyword>
	<keyword>Tdap</keyword>
	<keyword>Boostrix</keyword>
	<keyword>booster</keyword>
	<keyword>tetanus</keyword>
	<keyword>diphtheria</keyword>
</DOC>